BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 20305819)

  • 1. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
    David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
    PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone.
    Leblanc R; Lee SC; David M; Bordet JC; Norman DD; Patil R; Miller D; Sahay D; Ribeiro J; Clézardin P; Tigyi GJ; Peyruchaud O
    Blood; 2014 Nov; 124(20):3141-50. PubMed ID: 25277122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
    Boucharaba A; Serre CM; Grès S; Saulnier-Blache JS; Bordet JC; Guglielmi J; Clézardin P; Peyruchaud O
    J Clin Invest; 2004 Dec; 114(12):1714-25. PubMed ID: 15599396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis.
    Baker DL; Fujiwara Y; Pigg KR; Tsukahara R; Kobayashi S; Murofushi H; Uchiyama A; Murakami-Murofushi K; Koh E; Bandle RW; Byun HS; Bittman R; Fan D; Murph M; Mills GB; Tigyi G
    J Biol Chem; 2006 Aug; 281(32):22786-93. PubMed ID: 16782709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
    Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
    J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
    Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
    J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystallization and preliminary X-ray crystallographic analysis of human autotaxin.
    Inoue K; Tanaka N; Haga A; Yamasaki K; Umeda T; Kusakabe Y; Sakamoto Y; Nonaka T; Deyashiki Y; Nakamura KT
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2011 Apr; 67(Pt 4):450-3. PubMed ID: 21505238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATX-LPA receptor axis in inflammation and cancer.
    Liu S; Murph M; Panupinthu N; Mills GB
    Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD).
    Mori K; Kitayama J; Aoki J; Kishi Y; Shida D; Yamashita H; Arai H; Nagawa H
    Virchows Arch; 2007 Jul; 451(1):47-56. PubMed ID: 17554559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
    Li S; Wang B; Xu Y; Zhang J
    Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
    van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
    J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity.
    Ferry G; Tellier E; Try A; Grés S; Naime I; Simon MF; Rodriguez M; Boucher J; Tack I; Gesta S; Chomarat P; Dieu M; Raes M; Galizzi JP; Valet P; Boutin JA; Saulnier-Blache JS
    J Biol Chem; 2003 May; 278(20):18162-9. PubMed ID: 12642576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
    Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
    Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation.
    Harper K; Arsenault D; Boulay-Jean S; Lauzier A; Lucien F; Dubois CM
    Cancer Res; 2010 Jun; 70(11):4634-43. PubMed ID: 20484039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleiotropic activity of lysophosphatidic acid in bone metastasis.
    Peyruchaud O; Leblanc R; David M
    Biochim Biophys Acta; 2013 Jan; 1831(1):99-104. PubMed ID: 22710393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity.
    Gupte R; Patil R; Liu J; Wang Y; Lee SC; Fujiwara Y; Fells J; Bolen AL; Emmons-Thompson K; Yates CR; Siddam A; Panupinthu N; Pham TC; Baker DL; Parrill AL; Mills GB; Tigyi G; Miller DD
    ChemMedChem; 2011 May; 6(5):922-35. PubMed ID: 21465666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression.
    Panupinthu N; Lee HY; Mills GB
    Br J Cancer; 2010 Mar; 102(6):941-6. PubMed ID: 20234370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
    Yatomi Y
    Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
    Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
    J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.